In the Sept. 15 issue of Genes & Development, scientists lend new insights into how an aggressive form of acute lymphoblastic leukemia develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.
Post new comment